RU2011124894A - Триазолотиадиазоловый ингибитор протеинкиназы с-мет - Google Patents
Триазолотиадиазоловый ингибитор протеинкиназы с-мет Download PDFInfo
- Publication number
- RU2011124894A RU2011124894A RU2011124894/04A RU2011124894A RU2011124894A RU 2011124894 A RU2011124894 A RU 2011124894A RU 2011124894/04 A RU2011124894/04 A RU 2011124894/04A RU 2011124894 A RU2011124894 A RU 2011124894A RU 2011124894 A RU2011124894 A RU 2011124894A
- Authority
- RU
- Russia
- Prior art keywords
- disorder
- compound according
- agent
- pharmaceutically acceptable
- pharmaceutical composition
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 10
- 208000035475 disorder Diseases 0.000 claims abstract 10
- 239000003795 chemical substances by application Substances 0.000 claims abstract 6
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 6
- 206010017758 gastric cancer Diseases 0.000 claims abstract 4
- 230000002062 proliferating effect Effects 0.000 claims abstract 4
- 150000003839 salts Chemical class 0.000 claims abstract 4
- 201000001320 Atherosclerosis Diseases 0.000 claims abstract 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims abstract 2
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims abstract 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims abstract 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims abstract 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims abstract 2
- 239000002671 adjuvant Substances 0.000 claims abstract 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims abstract 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims abstract 2
- 230000001028 anti-proliverative effect Effects 0.000 claims abstract 2
- 210000004556 brain Anatomy 0.000 claims abstract 2
- 210000000481 breast Anatomy 0.000 claims abstract 2
- 230000000973 chemotherapeutic effect Effects 0.000 claims abstract 2
- 239000003937 drug carrier Substances 0.000 claims abstract 2
- 208000010749 gastric carcinoma Diseases 0.000 claims abstract 2
- 208000005017 glioblastoma Diseases 0.000 claims abstract 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims abstract 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims abstract 2
- 210000004185 liver Anatomy 0.000 claims abstract 2
- 208000014018 liver neoplasm Diseases 0.000 claims abstract 2
- 210000004072 lung Anatomy 0.000 claims abstract 2
- 208000020816 lung neoplasm Diseases 0.000 claims abstract 2
- 208000037819 metastatic cancer Diseases 0.000 claims abstract 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims abstract 2
- 210000000496 pancreas Anatomy 0.000 claims abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract 2
- 210000002307 prostate Anatomy 0.000 claims abstract 2
- 201000001514 prostate carcinoma Diseases 0.000 claims abstract 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims abstract 2
- 201000011549 stomach cancer Diseases 0.000 claims abstract 2
- 201000000498 stomach carcinoma Diseases 0.000 claims abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11603308P | 2008-11-19 | 2008-11-19 | |
| US61/116,033 | 2008-11-19 | ||
| PCT/US2009/064909 WO2010059668A1 (en) | 2008-11-19 | 2009-11-18 | A triazolothiadiazole inhibitor of c-met protein kinase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2011124894A true RU2011124894A (ru) | 2012-12-27 |
Family
ID=42027848
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011124894/04A RU2011124894A (ru) | 2008-11-19 | 2009-11-18 | Триазолотиадиазоловый ингибитор протеинкиназы с-мет |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US8217056B2 (enExample) |
| EP (1) | EP2365977B1 (enExample) |
| JP (1) | JP5596047B2 (enExample) |
| KR (1) | KR20110094285A (enExample) |
| CN (1) | CN102216309B (enExample) |
| AR (1) | AR074379A1 (enExample) |
| AU (1) | AU2009316756B2 (enExample) |
| BR (1) | BRPI0921509A2 (enExample) |
| CA (1) | CA2743000A1 (enExample) |
| CL (1) | CL2011001152A1 (enExample) |
| ES (1) | ES2393693T3 (enExample) |
| IL (1) | IL212906A0 (enExample) |
| MX (1) | MX2011005250A (enExample) |
| NZ (1) | NZ592825A (enExample) |
| RU (1) | RU2011124894A (enExample) |
| TW (1) | TW201024309A (enExample) |
| WO (1) | WO2010059668A1 (enExample) |
| ZA (1) | ZA201103170B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2166008A1 (en) * | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
| EP2166010A1 (en) * | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
| BRPI0921509A2 (pt) * | 2008-11-19 | 2016-03-08 | Vertex Pharma | inibidor triazolotiadiazol de proteína quinase c-met |
| MX2011012522A (es) * | 2009-05-28 | 2012-02-08 | Vertex Pharma | Inhibidores de pirazol sustituido de proteina cinasa c-met. |
| CN102448969A (zh) | 2009-05-28 | 2012-05-09 | 沃泰克斯药物股份有限公司 | C-met蛋白激酶抑制剂 |
| SG176574A1 (en) * | 2009-05-28 | 2012-01-30 | Vertex Pharma | Aminopyrazole triazolothiadiazole inhibitors of c-met protien kinase |
| CN109283279B (zh) * | 2017-07-21 | 2019-11-01 | 南京正大天晴制药有限公司 | 通过高效液相色谱法分离测定雷替曲塞及其对映异构体的方法 |
| CN109897054B (zh) * | 2017-12-08 | 2021-12-10 | 中国药科大学 | 三唑并噻二唑类c-Met激酶抑制剂的制备方法及其用途 |
| AU2020242287A1 (en) | 2019-03-21 | 2021-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A Dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5144532B2 (ja) * | 2005-11-30 | 2013-02-13 | バーテックス ファーマシューティカルズ インコーポレイテッド | ｃ−Ｍｅｔ阻害剤及び用法 |
| CA2651979A1 (en) * | 2006-05-30 | 2007-12-06 | Pfizer Products Inc. | Triazolopyridazine derivatives |
| WO2008144767A1 (en) * | 2007-05-21 | 2008-11-27 | Sgx Pharmaceuticals, Inc. | Heterocyclic kinase modulators |
| BRPI0921509A2 (pt) * | 2008-11-19 | 2016-03-08 | Vertex Pharma | inibidor triazolotiadiazol de proteína quinase c-met |
-
2009
- 2009-11-18 BR BRPI0921509A patent/BRPI0921509A2/pt not_active Application Discontinuation
- 2009-11-18 ES ES09756109T patent/ES2393693T3/es active Active
- 2009-11-18 AU AU2009316756A patent/AU2009316756B2/en not_active Ceased
- 2009-11-18 CN CN200980146238.2A patent/CN102216309B/zh not_active Expired - Fee Related
- 2009-11-18 NZ NZ592825A patent/NZ592825A/xx not_active IP Right Cessation
- 2009-11-18 RU RU2011124894/04A patent/RU2011124894A/ru unknown
- 2009-11-18 KR KR1020117011277A patent/KR20110094285A/ko not_active Withdrawn
- 2009-11-18 JP JP2011536613A patent/JP5596047B2/ja not_active Expired - Fee Related
- 2009-11-18 US US12/620,845 patent/US8217056B2/en not_active Expired - Fee Related
- 2009-11-18 MX MX2011005250A patent/MX2011005250A/es active IP Right Grant
- 2009-11-18 CA CA2743000A patent/CA2743000A1/en not_active Abandoned
- 2009-11-18 WO PCT/US2009/064909 patent/WO2010059668A1/en not_active Ceased
- 2009-11-18 EP EP09756109A patent/EP2365977B1/en active Active
- 2009-11-19 TW TW098139384A patent/TW201024309A/zh unknown
- 2009-11-19 AR ARP090104468A patent/AR074379A1/es unknown
-
2011
- 2011-04-29 ZA ZA2011/03170A patent/ZA201103170B/en unknown
- 2011-05-03 US US13/099,643 patent/US8343998B2/en not_active Expired - Fee Related
- 2011-05-16 IL IL212906A patent/IL212906A0/en unknown
- 2011-05-18 CL CL2011001152A patent/CL2011001152A1/es unknown
- 2011-08-10 US US13/206,954 patent/US20110301195A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0921509A2 (pt) | 2016-03-08 |
| KR20110094285A (ko) | 2011-08-23 |
| JP2012509279A (ja) | 2012-04-19 |
| NZ592825A (en) | 2013-01-25 |
| EP2365977A1 (en) | 2011-09-21 |
| ES2393693T3 (es) | 2012-12-27 |
| CA2743000A1 (en) | 2010-05-27 |
| US20110207774A1 (en) | 2011-08-25 |
| WO2010059668A1 (en) | 2010-05-27 |
| IL212906A0 (en) | 2011-07-31 |
| ZA201103170B (en) | 2012-08-29 |
| MX2011005250A (es) | 2011-07-29 |
| US8217056B2 (en) | 2012-07-10 |
| JP5596047B2 (ja) | 2014-09-24 |
| CN102216309A (zh) | 2011-10-12 |
| AR074379A1 (es) | 2011-01-12 |
| US20100234423A1 (en) | 2010-09-16 |
| EP2365977B1 (en) | 2012-10-03 |
| AU2009316756A1 (en) | 2010-05-27 |
| CN102216309B (zh) | 2014-05-07 |
| AU2009316756B2 (en) | 2016-02-25 |
| TW201024309A (en) | 2010-07-01 |
| US20110301195A1 (en) | 2011-12-08 |
| US8343998B2 (en) | 2013-01-01 |
| CL2011001152A1 (es) | 2012-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2011124894A (ru) | Триазолотиадиазоловый ингибитор протеинкиназы с-мет | |
| EP2620432A3 (en) | Diarylhydantoin compounds | |
| JP2012509279A5 (enExample) | ||
| RU2012118974A (ru) | Комбинации ингибитора pi3k и ингибитора мек | |
| EA201690322A1 (ru) | Терапевтически активные соединения и способы их применения | |
| JP2009242409A5 (enExample) | ||
| EA201290062A1 (ru) | Соединения, связывающие белки теплового шока, композиции и способы получения указанных соединений | |
| RU2016122731A (ru) | Функционализированные и замещенные индолы в качестве противораковых агентов | |
| LU92338I2 (fr) | Enzalutamide et ses sels pharmaceutiquement acceptables (XTANDI) | |
| EA200971026A1 (ru) | Новые макроциклические ингибиторы репликации вируса гепатита с | |
| JP2008535902A5 (enExample) | ||
| RU2012140185A (ru) | Ингибирование ангиогенеза | |
| CA2606719A1 (en) | Amorphous salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and process for producing the same | |
| EA201001196A1 (ru) | Соединения 4-пиридинона и их применение для лечения рака | |
| RU2010144637A (ru) | Замещенные гамма-лактамы в качестве терапевтических агентов | |
| PH12015501795A1 (en) | A novel composition for nonalcoholic fatty liver disease (nafld) | |
| EA201391629A1 (ru) | Ингибиторы цсж-1r для лечения опухолей головного мозга | |
| JP2017526662A5 (enExample) | ||
| JP2015522589A5 (enExample) | ||
| EA201270383A1 (ru) | Применение n-(4-((3-(2-амино-4-пиримидинил)-2-пиридинил)окси)фенил)-4-(4-метил-2-тиенил)-1-фталазинамина для лечения резистентного к антимитотическому агенту рака | |
| RU2017141446A (ru) | Энантиомеры 2-гидроксипроизводных жирных кислот | |
| JP2018538273A5 (enExample) | ||
| JP2015503596A5 (enExample) | ||
| JP2013544892A5 (enExample) | ||
| JP2009539994A5 (enExample) |